Search
Pentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedHydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. … Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics … Women undergoing abrupt menopause due to oophorectomy also experienced more severe symptoms than those going through a gradual transition.
Entacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxyl...
Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamideMixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200Calaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalAsparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].
Categories: Compounds used in a research, industrial, or household settingEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant
Chlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitAn anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Mixtures: Limbitrol DS, Nu-chlorax Capsules USPVon Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigationalThe human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. … The human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015.
Mixtures: IMMUNATE 500 IU/375 IU IV INFUZYONLUK TOZ ICEREN FLAKON, 1 ADET, IMMUNATE 1000 IU/750 IU IV INFUZYONLUK TOZ ICEREN FLAKON, 1 ADETCategories: von Willebrand factor and coagulation factor VIII in combinationIfosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIt is active as an alkylating agent and an immunosuppressive agent.
Products: IFO-CELL N 1000, IFO-cell N 1000; Solution for Infusion (1000mg per vial)